Odisha Approves Pharma & MedTech Policy to Build Sector Hubs & Boost Investment

The new policy will help Odisha build a competitive ecosystem for pharmaceutical and MedTech manufacturing, offering investors modern infrastructure, incentives and streamlined approvals to scale operations.

The Odisha Cabinet has approved a new Pharma & MedTech Policy designed to position the state as a competitive hub for pharmaceutical manufacturing, medical device production, and healthcare innovation.

The policy is expected to drive large-scale investment and accelerate the development of sector-specific industrial clusters equipped with advanced infrastructure and streamlined regulatory processes.

Announcing the approval, Chief Secretary Pradeep Kumar Jena said the new policy will give Odisha a stronger presence in India’s expanding healthcare manufacturing landscape. “The Pharma and MedTech sector have significant potential for growth,” he noted.

Adding that the policy aims to support investors with incentives, land availability and plug-and-play facilities to help companies scale faster.

The initiative includes the creation of dedicated industrial hubs to attract pharmaceutical companies, bulk drug manufacturers, diagnostic device producers and MedTech innovators.

Industries Secretary Hemant Sharma highlighted that the policy is designed to help Odisha tap into rising demand for domestic manufacturing. “We see this as an opportunity to build a reliable, high-quality ecosystem that supports both innovation and large-scale production,” he said.

By expanding manufacturing capacities within the state, Odisha aims to strengthen supply chains and provide a conducive environment for research, technology upgrades and global export opportunities.

The Cabinet also emphasized the policy’s potential to create high-skilled employment and foster industry-academia collaboration across pharmaceuticals and MedTech.

Hemant Sharma mentioned the state is prepared to offer investor-friendly support. “Our focus is on creating long-term value for companies and ensuring Odisha becomes a preferred destination for the life sciences sector.”

With the policy now in place, the government is expected to initiate development work within planned industrial zones and begin outreach to domestic and international manufacturers.

Related Posts

Gene Therapy for Cholesterol: Initial Test Results Cheer

Eli Lilly working on single-dose drug to be administered via IV for long-term gain Mumbai: For millions of heart patients struggling with elevated levels of cholesterol, there is a ray…

US Biotech Regeneron to launch Global Capability Centre in Hyderabad

Regeneron Pharmaceuticals, Inc. has announced plans to establish the Regeneron Global Capability Centre (GCC) in Hyderabad, a strategic investment that deepens its global operations and scales business functions to advance…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Gene Therapy for Cholesterol: Initial Test Results Cheer

Gene Therapy for Cholesterol: Initial Test Results Cheer

US Biotech Regeneron to launch Global Capability Centre in Hyderabad

US Biotech Regeneron to launch Global Capability Centre in Hyderabad

Popped the Pill, Paid the Price to Potentially Fatal Skin Syndrome

Popped the Pill, Paid the Price to Potentially Fatal Skin Syndrome

Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

STF busts fake meds racket spread across 6 states

STF busts fake meds racket spread across 6 states